Latham & Watkins Advises Aziyo Biologics in its Initial Public Offering

Aziyo Biologics, Inc. has announced the pricing of its initial public offering of 2,941,176 shares of common stock, consisting of 2,205,882 shares of Class A common stock and 735,294 shares of Class B common stock, each at a public offering price of US$17.00 per share, before deducting underwriting discounts and commissions. All of the common stock is being offered by Aziyo. The offering is expected to close on October 13, 2020, subject to customary closing conditions. In addition, Aziyo has granted the underwriters a 30-day option to purchase up to an additional 441,176 shares of its Class A common stock at the initial public offering price less the underwriting discounts and commissions. The gross proceeds of the offering are expected to be US$50.0 million, excluding any exercise of the underwriters’ option. 

Latham & Watkins LLP represents Aziyo Biologics, Inc. in the offering with a capital markets team led by Boston/New York partner Wesley Holmes and Orange County/New York partner Charles Ruck, with New York associates Lindsey Mills, Samuel Niles and Milo LeDoux and Boston associate Emily Henderson. Advice was also provide on tax matters by New York partner Lisa Watts, with New York associate Lauren Bewley; on benefits and compensation matters by New York counsel Rifka Singer, with New York associate Anne Bracaglia; and on regulatory matters by Washington, D.C. of counsel Carolyne Hathaway, Brussels partner Hector Armengod, with Bay Area counsel Betty Pang and Washington, D.C. associate Chad Jennings.